Comparison of Clinical Efficacy of Three Different NeoadjuvantApproaches (Chemotherapy Combined Vaginal Intracavitary Irradiation, Neoadjuvant Chemotherapy Alone or Radiotherapy) Combined with Surgery for Patients with Stage Ib2 and IIa2 Cervical Canc


A total of 285 patients with stage Ib2 and IIa2 cervical cancer were categorized into three groups, andreceived preoperative neoadjuvant chemotherapy combined with vaginal intracavitary irradiation, neoadjuvantchemotherapy alone or radiotherapy, respectively. The effective rate of 70.6 % in group 1 was much higher than41.4% in group 2 (P=0.000) and 46.9 % in group 3 (P=0.000); The percentage of patients receiving postoperativeadjuvant therapy was 44.1% in group 1, much lower than 67.8% in group 2 (P=0.001) and 64.6% in group 3(P=0.004); The percentage of patients with no postoperative risk factor in group 1 was 52.0%, much higher than32.2% in group 2 (P=0.006) and 35.4% in group 3 (P=0.019); The occurrence rate of surgery-related complicationsin groups 1, 2 and 3 were 29.4%, 28.7%, and 33.3%, respectively, with no statistical differences among the groups(P=0.981). Regarding preoperative neoadjuvant complications, none were obvious in group 3, while occurrencerates of myelosuppression in groups 1 and 2 were 89.1% and 86.6%, of nausea and vomitting were 78.4%and 78.2%, but without significant differences (all P>0.05). Among 166 patients who received postoperativeadjuvant therapy in the three groups, the occurrence rates were: 65.4%, 64.3% and 61.1% respectively formyelosuppression; 42.3%, 38.1%, and 38.9% for nausea and vomiting; 9.6%, 9.5% and 9.7% for urocystitis;and 63.5%, 69.0% and 65.3% enteritis and rectitis. There were no statistically significant differences amongthem (all P>0.05). The five-year disease-free survival rates (DFS) in groups 1, 2, 3 were 78.3%, 75.1%, 80.9%,respectively; the five-year overall survival rates (OS) were 81.4%, 78.2%, and 81.1%, respectively. The five-yearOS of 166 patients receiving postoperative in the three groups were 72.4%, 69.5%, and 71.8%, respectively, withno significant variation (all P>0.05). Although there were no differences among three groups in DFS and OS,preoperative neoadjuvant chemotherapy combined with intracavitary radiotherapy may increase the effectiverate and the percentage of patients with no postoperative risk factors and decrease the percentage of patientsreceiving postoperative adjuvant therapy, thereby decreasing complications indirectly and increasing qualityof life.